NU553 Unit 2 Study Guide

NU553 Unit 2 Study Guide

Student Name

Purdue University Global

NU553 Advanced Pharmacology and Pharmacotherapeutics

Prof. Name:

Date

NU553 Unit 2 Study Guide

Understanding psychiatric pharmacology and pain management requires knowledge of neurotransmitter activity, medication mechanisms, therapeutic monitoring, and evidence-based prescribing practices. The most important clinical principles include matching medications to patient-specific symptoms, evaluating risks and benefits, monitoring treatment response, and integrating medication therapy with psychotherapy, behavioral interventions, and patient education. Effective pharmacologic management is not based only on selecting a medication; it requires continuous assessment of safety, effectiveness, adherence, and individual patient needs.

Advanced practice providers use pharmacology principles to understand how medications influence brain chemistry, manage psychiatric symptoms, reduce pain, and improve quality of life. A strong understanding of neurotransmitters and medication mechanisms helps clinicians make informed prescribing decisions while minimizing adverse effects and improving patient outcomes.

The Role of Neurotransmitters in Psychiatric Pharmacology

Neurotransmitters are chemical messengers that allow communication between nerve cells and regulate essential functions such as mood, cognition, sleep, motivation, attention, and emotional responses. Psychiatric medications work by modifying neurotransmitter activity to correct functional imbalances associated with mental health conditions.

Common neurotransmitters involved in psychiatric disorders include:

• Serotonin: Influences mood regulation, anxiety, sleep, and emotional stability.

• Norepinephrine: Plays a role in attention, energy, stress response, and alertness.

• Dopamine: Affects motivation, reward processing, movement, and psychotic symptoms.

• Gamma-aminobutyric acid (GABA): Produces inhibitory effects that reduce excessive neuronal activity and anxiety.

• Glutamate: Regulates learning, memory, and excitatory brain signaling.

Medication selection requires clinicians to consider:

• The patient’s primary symptoms

• Previous treatment response

• Medical comorbidities

• Potential medication interactions

• Adverse effect risks

• Patient preferences and treatment goals

Pharmacotherapy is most effective when combined with evidence-based psychotherapy, lifestyle modification, behavioral strategies, and ongoing patient education.

Neurotransmitter Changes Associated With Psychiatric Disorders

Understanding neurotransmitter patterns helps clinicians select medications that target specific symptom clusters. Although psychiatric disorders involve complex biological processes, neurotransmitter abnormalities provide a foundation for treatment planning.

These relationships guide medication selection, but treatment decisions should always be individualized because psychiatric disorders involve multiple biological, psychological, and environmental factors.

Antidepressant Medications: Essential Pharmacology Concepts

Antidepressants are primarily used for depressive disorders but are also commonly prescribed for anxiety disorders, obsessive-compulsive disorder, panic disorder, and some chronic pain conditions.

The goal of antidepressant therapy is to improve mood symptoms, restore functional ability, and reduce relapse risk while maintaining medication safety.

Selective Serotonin Reuptake Inhibitors (SSRIs)

Selective serotonin reuptake inhibitors (SSRIs) are considered first-line medications for many depressive and anxiety disorders because they demonstrate strong effectiveness, improved tolerability, and fewer serious adverse effects compared with older antidepressant classes.

SSRIs work by blocking serotonin reuptake, increasing serotonin availability within the synaptic space and improving neurotransmission.

Common SSRIs include:

• Sertraline

• Fluoxetine

• Citalopram

• Escitalopram

SSRIs are frequently selected because they:

• Have favorable safety profiles

• Are effective for depression and anxiety

• Generally have fewer anticholinergic effects than older antidepressants

• Are suitable for long-term management in many patients

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs increase both serotonin and norepinephrine activity. They may be particularly useful when depression occurs with symptoms such as fatigue, low energy, or chronic neuropathic pain.

Common SNRIs include:

• Venlafaxine

• Duloxetine

Duloxetine is frequently considered when depressive symptoms occur alongside conditions such as diabetic neuropathy or other chronic pain syndromes because of its dual psychiatric and analgesic benefits.

Other Antidepressant Classes

Different antidepressant medications may be selected based on individual symptom patterns and adverse effect considerations.

High-Yield Antidepressant Medication Pearls

Medication selection should consider the patient’s symptom pattern rather than diagnosis alone.

Important clinical considerations include:

Bupropion

• Increases dopamine and norepinephrine activity

• May improve energy and concentration

• May reduce antidepressant-associated sexual dysfunction

• May be avoided in patients with seizure disorders

Mirtazapine

• Has sedating properties because of histamine receptor effects

• May benefit patients experiencing insomnia or decreased appetite

• Can contribute to weight gain

Monitoring Patients Receiving Antidepressants

Patients beginning antidepressant therapy require close follow-up, especially during the first several weeks of treatment. Clinical improvement in energy and motivation may occur before complete mood improvement, which can increase suicide risk in vulnerable individuals.

Providers should monitor for:

• Worsening depression

• Suicidal thoughts or behaviors

• Medication adherence

• Early adverse effects

• Serotonin syndrome symptoms

Serotonin syndrome may present with:

• Agitation

• Confusion

• Sweating

• Tremors

• Increased heart rate

• Muscle rigidity

• Fever

Antidepressants should generally be tapered gradually rather than discontinued abruptly to reduce withdrawal symptoms.

Pharmacologic Treatment of Anxiety Disorders

Anxiety disorders involve excessive fear, worry, and physiological arousal caused by altered regulation of neurotransmitter systems, particularly serotonin, norepinephrine, and GABA.

Long-term treatment typically focuses on medications that provide symptom improvement without creating dependence risks.

Benzodiazepines

Benzodiazepines enhance GABA activity, producing rapid reduction in anxiety symptoms. Because of their fast onset, they may be useful for short-term anxiety management or acute episodes.

Common concerns include:

• Tolerance development

• Physical dependence

• Withdrawal symptoms

• Sedation

• Increased fall risk in older adults

• Potential misuse

Long-term benzodiazepine therapy is generally avoided when safer alternatives are available.

Patients should be educated to:

• Avoid abrupt discontinuation

• Avoid combining benzodiazepines with alcohol or other central nervous system depressants

• Use controlled medications only as prescribed

Buspirone

Buspirone is a non-benzodiazepine medication commonly used for generalized anxiety disorder.

Clinical characteristics include:

• Serotonin receptor activity

• Minimal sedation

• Low abuse potential

• Delayed therapeutic effect compared with benzodiazepines

Because buspirone requires several weeks for maximum benefit, it is not typically used for immediate relief of severe anxiety episodes.

First-Line Long-Term Anxiety Treatment

For many chronic anxiety disorders, SSRIs and SNRIs are preferred because they provide effective symptom control with lower dependence risk.

Medication therapy is most effective when combined with:

• Cognitive behavioral therapy (CBT)

• Relaxation training

• Mindfulness-based interventions

• Exercise

• Sleep improvement strategies

Antipsychotic Medications: Understanding Clinical Differences

Antipsychotic medications are primarily used for schizophrenia, schizoaffective disorder, bipolar disorder, and other conditions involving psychosis.

They reduce symptoms by modifying dopamine and serotonin activity within specific brain pathways.

First-Generation Antipsychotics

First-generation antipsychotics primarily block dopamine D2 receptors.

They are effective for reducing positive symptoms of schizophrenia, including:

• Hallucinations

• Delusions

• Disorganized thinking

However, they are associated with increased risk of extrapyramidal symptoms (EPS).

EPS may include:

• Muscle stiffness

• Tremors

• Restlessness (akathisia)

• Abnormal involuntary movements

Long-term treatment may lead to tardive dyskinesia, characterized by repetitive involuntary movements involving the:

• Face

• Tongue

• Jaw

• Limbs

Second-Generation Antipsychotics

Second-generation antipsychotics affect both dopamine and serotonin receptors. They generally have a lower risk of movement-related adverse effects compared with first-generation medications.

However, they carry increased risk of metabolic complications.

Monitoring should include:

• Body weight

• Blood pressure

• Blood glucose

• Lipid profile

• Metabolic laboratory values

• Medication adherence

Clozapine Monitoring Requirements

Clozapine is an effective antipsychotic for treatment-resistant schizophrenia but requires strict monitoring because of the risk of agranulocytosis, a potentially dangerous reduction in white blood cells.

Patients receiving clozapine require:

• Regular complete blood count (CBC) monitoring

• Assessment for infection symptoms

• Ongoing evaluation of treatment response

Neuroleptic Malignant Syndrome (NMS)

Neuroleptic malignant syndrome is a rare but life-threatening reaction associated with antipsychotic medications.

Clinical features include:

• Severe muscle rigidity

• Fever

• Altered mental status

• Autonomic instability

• Elevated creatine kinase levels

Risk factors include:

• High-potency antipsychotics

• Rapid dose increases

• Dehydration

• Previous history of NMS

NMS requires immediate medical evaluation and treatment.

Mood Stabilizers in Bipolar Disorder Management

Mood stabilizers reduce mood fluctuations and help prevent manic and depressive episodes in bipolar disorder.

Lithium Therapy

Lithium remains one of the most effective medications for bipolar disorder, particularly for preventing manic episodes and reducing suicide risk.

Because lithium has a narrow therapeutic range, careful monitoring is essential.

Typical therapeutic serum levels range approximately from:

• 0.6 to 1.2 mEq/L

Monitoring includes:

• Serum lithium concentrations

• Kidney function

• Thyroid function

• Electrolyte balance

Patients should receive education regarding:

• Maintaining consistent fluid intake

• Avoiding sudden sodium changes

• Reporting symptoms of toxicity

• Discussing NSAID use with healthcare providers

Signs of lithium toxicity may include:

• Tremors

• Confusion

• Severe gastrointestinal symptoms

• Coordination problems

Anticonvulsant Mood Stabilizers

Alternative mood stabilizers include:

• Valproic acid

• Lamotrigine

• Carbamazepine

Monitoring considerations include:

• Liver function testing

• Blood counts when appropriate

• Skin reactions

• Medication interactions

Lamotrigine requires careful dose escalation because rapid increases may increase the risk of serious skin reactions, including Stevens-Johnson syndrome.

ADHD Medications: Pharmacologic Management of Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is associated with impaired regulation of dopamine and norepinephrine pathways, particularly within the prefrontal cortex, which controls attention, executive functioning, impulse regulation, and working memory.

Pharmacologic treatment improves concentration, reduces impulsivity, and enhances functional performance when combined with behavioral strategies and patient education.

Stimulant Medications for ADHD

Stimulants are considered first-line pharmacologic treatments for many individuals with ADHD because of their strong evidence base and effectiveness in improving core symptoms.

Common stimulant medications include:

• Methylphenidate preparations

• Amphetamine-based medications

Stimulants increase dopamine and norepinephrine activity in brain regions involved in attention and behavioral regulation.

Before initiating stimulant therapy, clinicians should evaluate:

• Cardiovascular history

• Blood pressure and heart rate

• Family history of cardiac disease

• Substance use history

• Sleep patterns

• Appetite and nutritional status

Non-Stimulant ADHD Medications

Non-stimulant medications may be considered when stimulants are ineffective, poorly tolerated, or associated with increased risk.

Common options include:

• Atomoxetine

• Alpha-2 adrenergic agonists such as guanfacine and clonidine

Non-stimulant medications may be beneficial for patients with:

• Cardiovascular concerns

• Substance misuse risk

• Significant stimulant-related adverse effects

Monitoring Patients Receiving ADHD Medications

Ongoing monitoring helps ensure medication effectiveness and reduces safety concerns.

Clinicians should regularly assess:

• Blood pressure

• Heart rate

• Weight changes

• Appetite suppression

• Sleep quality

• Symptom improvement

• Medication adherence

Patients and families should receive education regarding appropriate medication use, safe storage, and the importance of avoiding medication sharing.

Pharmacologic Management of Sleep Disorders

Sleep disorders require a comprehensive approach that addresses behavioral, psychological, and medical contributors. Medication therapy should generally be considered when non-pharmacologic interventions are insufficient or when short-term symptom relief is clinically appropriate.

Non-Pharmacologic Treatment as the First Approach

Behavioral interventions remain the foundation of insomnia treatment.

Evidence-based strategies include:

• Maintaining consistent sleep and wake times

• Creating a relaxing bedtime routine

• Limiting caffeine and stimulating activities before sleep

• Practicing relaxation techniques

• Cognitive behavioral therapy for insomnia (CBT-I)

• Mindfulness-based approaches

CBT-I is considered an effective long-term treatment because it addresses behaviors and thought patterns that contribute to chronic insomnia.

Common Sleep Medications

When medication therapy is appropriate, clinicians should use the lowest effective dose for the shortest appropriate duration.

Common medications include:

Zolpidem

• A non-benzodiazepine hypnotic

• May improve sleep initiation

• Requires monitoring for complex sleep behaviors

Ramelteon

• Acts on melatonin receptors

• May assist with sleep-wake cycle regulation

• Has minimal dependence risk

Trazodone

• Frequently used off-label for insomnia

• May cause sedation and orthostatic hypotension

Low-dose doxepin

• May improve sleep maintenance

• Requires consideration of anticholinergic effects

Potential adverse effects requiring monitoring include:

• Daytime sedation

• Cognitive impairment

• Falls

• Confusion in older adults

• Abnormal sleep behaviors

Medication Considerations for Special Populations

Medication selection must be individualized according to age, pregnancy status, medical conditions, and risk factors. The same medication may produce different outcomes depending on patient characteristics.

Older Adults

Older adults are more vulnerable to medication-related complications because of age-related changes in metabolism, kidney function, and medication sensitivity.

Common concerns include:

• Increased sedation

• Falls

• Cognitive impairment

• Anticholinergic effects

• Drug interactions

Prescribing principles for older adults include:

• Start with low doses

• Increase doses gradually

• Review medications regularly

• Avoid unnecessary medications

This approach reduces adverse effects while maintaining therapeutic effectiveness.

Pregnancy Considerations

Psychiatric medication decisions during pregnancy require careful evaluation of maternal benefits and fetal risks.

Important considerations include:

• Severity of maternal symptoms

• Previous treatment response

• Medication safety data

• Risk of untreated psychiatric illness

Valproic acid is generally avoided during pregnancy because of significant fetal risks, including neural tube defects and developmental concerns.

SSRIs may be considered when benefits outweigh potential risks, with treatment decisions individualized through shared decision-making.

Adolescents

Adolescents receiving psychiatric medications require careful monitoring, particularly when initiating antidepressants.

Providers should assess for:

• Worsening depression

• Suicidal thoughts

• Behavioral changes

• Medication adherence

• Family support systems

Education should involve both the patient and caregivers when appropriate.

Patients With Substance Use Disorders

Patients with substance use disorders require careful medication selection to reduce misuse potential.

Clinical considerations include:

• Avoiding unnecessary controlled substances

• Evaluating addiction history

• Considering non-addictive alternatives

• Monitoring prescription use

• Coordinating care with behavioral health specialists

Ethical and Legal Responsibilities in Prescribing Practice

Advanced practice providers must follow ethical, legal, and professional standards when prescribing medications.

Safe prescribing requires balancing symptom management with patient safety.

Essential responsibilities include:

• Practicing evidence-based prescribing

• Obtaining informed consent

• Engaging patients in shared decision-making

• Maintaining accurate documentation

• Reviewing prescription monitoring databases

• Evaluating medication risks and benefits

• Preventing misuse and diversion

Controlled Substance Prescribing Responsibilities

When prescribing controlled medications, clinicians should:

• Review the Prescription Drug Monitoring Program (PDMP)

• Assess misuse risk

• Establish treatment expectations

• Monitor medication effectiveness

• Document clinical reasoning

Controlled medications require ongoing reassessment because risks may change throughout treatment.

Clinical Monitoring During Pharmacologic Treatment

Effective medication management requires ongoing evaluation rather than a single prescribing decision.

Monitoring allows clinicians to determine whether treatment is improving symptoms while identifying adverse effects early.

Baseline Laboratory Assessment

Depending on the medication, baseline testing may include:

• Complete blood count (CBC)

• Liver function tests

• Kidney function tests

• Electrolytes

• Blood glucose

• Lipid profile

• Pregnancy testing when clinically appropriate

Follow-Up Assessment

Follow-up visits should evaluate:

• Symptom improvement

• Medication adherence

• Side effects

• Functional improvement

• Patient satisfaction

• Treatment goals

Validated clinical tools may improve monitoring accuracy.

Examples include:

• PHQ-9 for depression severity

• GAD-7 for anxiety symptoms

These assessments are commonly repeated several weeks after treatment initiation to evaluate response.

Pain Management Principles in Clinical Practice

Effective pain management begins with identifying the underlying pain mechanism rather than treating pain intensity alone. A comprehensive approach combines medication therapy, non-pharmacologic interventions, patient education, and functional goals.

The primary goals of pain management are:

• Reduce pain severity

• Improve physical function

• Increase quality of life

• Minimize medication-related harm

Types of Pain and Clinical Characteristics

Pain classification helps clinicians select appropriate treatments.

Neuropathic pain often responds better to medications that modify nerve signaling rather than traditional analgesics alone.

Mechanism-Based Pain Treatment

Pain therapy should match the underlying mechanism.

Individual patient factors, including kidney function, gastrointestinal risk, cardiovascular status, and medication interactions, should guide treatment selection.

Non-Pharmacologic Approaches for Pain Management

Multimodal pain management improves outcomes by combining medication therapy with supportive interventions.

Evidence-based approaches include:

• Physical therapy

• Heat and cold application

• Massage therapy

• Cognitive behavioral therapy

• Therapeutic neuroscience education

• Acupuncture

• Transcutaneous electrical nerve stimulation (TENS)

• Mindfulness and relaxation techniques

These interventions can reduce medication requirements and improve long-term function.

Co-Analgesic Medications for Chronic Pain

Co-analgesics are medications originally developed for other conditions but found effective in specific pain syndromes.

Common examples include:

• Duloxetine

• Venlafaxine

• Amitriptyline

• Gabapentin

• Pregabalin

• Lidocaine patches

• Baclofen

• Tizanidine

• Cyclobenzaprine

These medications may improve pain control while reducing reliance on opioid therapy.

Interventional Treatment Options for Chronic Pain

Patients with persistent pain lasting several months may benefit from procedural interventions.

Potential options include:

• Nerve blocks

• Trigger-point injections

• Epidural steroid injections

• Radiofrequency procedures

• Neuromodulation therapies

• Vertebroplasty or kyphoplasty when clinically indicated

Interventional approaches should be considered as part of a broader pain management plan.

Safe Opioid Prescribing and Opioid Use Disorder Management

Opioids may provide significant pain relief but require careful assessment because of risks including tolerance, dependence, overdose, and misuse.

Safe opioid prescribing emphasizes:

• Using non-opioid treatments when appropriate

• Prescribing the lowest effective dose

• Establishing functional treatment goals

• Monitoring for misuse

• Educating patients about overdose prevention

Opioid Risk Assessment

Before initiating opioid therapy, clinicians should evaluate:

• Pain history

• Functional limitations

• Substance use history

• Mental health conditions

• Prescription monitoring information

Risk assessment tools such as the Opioid Risk Tool (ORT) may support clinical decision-making.

Medication Treatment for Opioid Use Disorder

Evidence-based medications for opioid use disorder include:

• Methadone

• Buprenorphine-containing medications

• Naloxone for overdose reversal

Treatment goals include:

• Reducing opioid cravings

• Preventing relapse

• Improving daily functioning

• Supporting recovery

Key Clinical Takeaways

• Neurotransmitter activity guides medication selection in psychiatric disorders.

• SSRIs and SNRIs remain common first-line treatments for depression and chronic anxiety.

• Lithium requires ongoing monitoring because of its narrow therapeutic range.

• Antipsychotic therapy requires evaluation for metabolic effects and movement disorders.

• ADHD medications require cardiovascular and growth monitoring.

• Behavioral interventions are essential components of insomnia treatment.

• Pain management is most effective when using multimodal strategies.

• Safe opioid prescribing requires risk assessment, monitoring, and patient education.

Frequently Asked Questions

What neurotransmitters are associated with depression?

Depression is commonly associated with dysregulation of serotonin, norepinephrine, and dopamine pathways. These neurotransmitter changes influence mood, motivation, energy, and emotional regulation and provide the basis for antidepressant treatment.

Why are SSRIs commonly used as first-line antidepressants?

SSRIs are frequently preferred because they provide effective symptom improvement with generally favorable safety profiles, fewer serious adverse effects than older antidepressants, and good long-term tolerability.

What monitoring is required for lithium therapy?

Lithium therapy requires monitoring of serum lithium levels, kidney function, thyroid function, hydration status, and symptoms of toxicity because lithium has a narrow therapeutic range.

How should chronic pain be treated?

Chronic pain should be managed using a multimodal approach that combines appropriate medications, physical therapies, behavioral interventions, patient education, and regular reassessment of treatment effectiveness.

What should clinicians monitor when prescribing antipsychotics?

Clinicians should monitor metabolic parameters such as weight, blood glucose, lipid levels, and blood pressure while also assessing movement-related adverse effects and treatment response.

What is the safest approach to opioid prescribing?

The safest approach involves careful patient assessment, use of non-opioid therapies when possible, functional treatment goals, ongoing monitoring, and education regarding overdose and dependence risks.

References 

American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association Publishing.
https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841

Bandelow, B., Michaelis, S., & Wedekind, D. (2022). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 24(1), 1–15.
https://www.tandfonline.com/doi/full/10.1080/19585969.2022.2042160

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222).
https://www.nice.org.uk/guidance/ng222

NU553 Unit 2 Study Guide

National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms (NG215).
https://www.nice.org.uk/guidance/ng215

Substance Abuse and Mental Health Services Administration. (2024). TIP 63: Medications for opioid use disorder.
https://store.samhsa.gov/product/tip-63-medications-opioid-use-disorder

Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
https://www.cambridge.org/core/books/stahls-essential-psychopharmacology/